瘤内递送tavo质粒在转移性黑色素瘤中引发全身免疫应答
这项开放标签II期试验在晚期黑色素瘤患者中瘤内注射编码IL-12的质粒tavo并电穿孔,主要研究队列客观缓解率35.7%、完全缓解率17.9%,中位无进展生存3.7个月,中位随访29.7个月时中位总生存未达到;全部队列中46%患者至少一个未注射病灶消退,但适应性免疫抵抗限制了疗效。
要点
- 瘤内tavo电穿孔在晚期黑色素瘤中耐受良好并诱导全身免疫应答。
- 主要研究队列客观缓解率35.7%,完全缓解率17.9%。
- 未注射病灶也可消退,但适应性免疫抵抗限制应答。
核心结论
- 瘤内tavo电穿孔治疗晚期黑色素瘤耐受良好,可诱导全身免疫应答并使注射及未注射病灶消退。
- 适应性免疫抵抗限制了tavo的疗效。
研究设计与样本
- 前瞻性开放标签II期临床试验(NCT01502293),纳入III/IV期黑色素瘤患者。
- 主要研究方案为瘤内注射tavo 0.5 mg/ml后电穿孔(六脉冲,1500 V/cm),第1、5、8天给药,每90天重复。
- 另有两个替代给药方案探索队列,并对治疗前后样本进行PD-L1、流式细胞术及免疫相关基因表达分析。
主要发现
- 主要研究队列客观总缓解率为35.7%,全部队列为29.8%。
- 主要研究队列完全缓解率为17.9%,全部队列为10.6%。
- 主要研究队列中位无进展生存期为3.7个月,中位随访29.7个月时中位总生存期未达到。
- 全部队列中46%有未注射病灶的患者至少一个未注射病灶消退,25%所有未治疗病灶净消退。
- 转录组和免疫组化分析显示免疫激活和共刺激转录本上调,但适应性免疫抵抗也增加。
临床怎么用
- 瘤内tavo电穿孔可作为晚期黑色素瘤的一种耐受良好的局部治疗策略,并可能诱导远端病灶消退。
- 治疗中需关注适应性免疫抵抗对疗效的限制,可能需联合策略克服抵抗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interleukin 12 (IL-12) is a pivotal regulator of innate and adaptive immunity. We conducted a prospective open-label, phase II clinical trial of electroporated plasmid IL-12 in advanced melanoma patients (NCT01502293). PATIENTS AND METHODS: Patients with stage III/IV melanoma were treated intratumorally with plasmid encoding IL-12 (tavokinogene telseplasmid; tavo), 0.5 mg/ml followed by electroporation (six pulses, 1500 V/cm) on days 1, 5, and 8 every 90 days in the main study and additional patients were treated in two alternative schedule exploration cohorts. Correlative analyses for programmed death-ligand 1 (PD-L1), flow cytometry to assess changes in immune cell subsets, and analysis of immune-related gene expression were carried out on pre- and post-treatment samples from study patients, as well as from additional patients treated during exploration of additional dosing schedules beyond the pre-specified protocol dosing schedule. Response was measured by study-specific criteria to maximize detection of latent and potentially transient immune responses in patients with multiple skin lesions and toxicities were graded by the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). RESULTS: The objective overall response rate was 35.7% in the main study (29.8% in all cohorts), with a complete response rate of 17.9% (10.6% in all cohorts). The median progression-free survival in the main study was 3.7 months while the median overall survival was not reached at a median follow up of 29.7 months. A total of 46% of patients in all cohorts with uninjected lesions experienced regression of at least one of these lesions and 25% had a net regression of all untreated lesions. Transcriptomic and immunohistochemistry analysis showed that immune activation and co-stimulatory transcripts were up-regulated but there was also increased adaptive immune resistance. CONCLUSIONS: Intratumoral Tavo was well tolerated and led to systemic immune responses in advanced melanoma patients. While tumor regression and increased immune infiltration were observed in treated as well as untreated/distal lesions, adaptive immune resistance limited the response.
引用
- Algazi A, Bhatia S, Agarwala S, et al. Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020. PMID: 32147213. doi:10.1016/j.annonc.2019.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。